NGS Sales Specialist - MidWest
Twist BioscienceFull Time
Mid-level (3 to 4 years), Senior (5 to 8 years)
Candidates should possess a Bachelor’s degree in life science, biology, business, or marketing, with an MBA being preferred. They must have at least 3 years of direct account management experience in a molecular diagnostic setting, specifically with a focus on MRD testing, and a proven track record of revenue generation within a diagnostic, pharmaceutical, or biotechnology company. Strong knowledge of the payer and reimbursement environment in oncology is required, along with proficiency in Microsoft Office products, particularly Excel and PowerPoint, and regular use of Salesforce.com.
The MRD Clinical Account Executive will drive the adoption of Tempus’s MRD testing services within the specified territory, focusing on major U.S. cancer centers, health systems, and community practices, engaging with Key Opinion Leaders (KOLs), clinicians, and decision-makers to establish and expand business opportunities. They will develop strategic plans for acquiring new clients and retaining existing ones, maximizing client-bill contracting opportunities, implement laboratory services agreements (LSAs) with institutions, collaborate with various sales roles within Tempus, identify and develop partnership opportunities between oncology clients and Tempus, provide feedback to Tempus leadership based on market analysis, and develop and implement a comprehensive business plan for the territory.
AI-driven healthcare data analysis platform
Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.